Targeting Prodromal Alzheimer Disease With Avagacestat

Abstract

disease (AD) is important for clinical management and affords the opportunity to assess potential disease-modifying agents in clinical trials. To our knowledge, this is the first report of a randomized trial to prospectively enrich a study population with prodromal AD (PDAD) defined by cerebrospinal fluid (CSF) biomarker criteria and mild cognitive impairment (MCI) symptoms. OBJECTIVES To assess the safety of the γ-secretase inhibitor avagacestat in PDAD and to determine whether CSF biomarkers can identify this patient population prior to clinical diagnosis of dementia. DESIGN, SETTING, AND PARTICIPANTS A randomized, placebo-controlled phase 2 clinical trial with a parallel, untreated, nonrandomized observational cohort of CSF biomarker-negative participants was conducted May 26, 2009, to July 9, 2013, in a multicenter global population. Of 1358 outpatients screened, 263 met MCI and CSF biomarker criteria for randomization into the treatment phase. One hundred two observational cohort participants who met MCI criteria but were CSF biomarker-negative were observed during the same study period to evaluate biomarker assay sensitivity. INTERVENTIONS Oral avagacestat or placebo daily. MAIN OUTCOMES AND MEASURE Safety and tolerability of avagacestat. RESULTS Of the 263 participants in the treatment phase, 132 were randomized to avagacestat and 131 to placebo; an additional 102 participants were observed in an untreated observational cohort. Avagacestat was relatively well tolerated with low discontinuation rates (19.6%) at a dose of 50 mg/d, whereas the dose of 125 mg/d had higher discontinuation rates (43%), primarily attributable to gastrointestinal tract adverse events. Increases in nonmelanoma skin cancer and nonprogressive, reversible renal tubule effects were observed with avagacestat. Serious adverse event rates were higher with avagacestat (49 participants [37.1%]) vs placebo (31 [23.7%]), attributable to the higher incidence of nonmelanoma skin cancer. At 2 years, progression to dementia was more frequent in the PDAD cohort (30.7%) vs the observational cohort (6.5%). Brain atrophy rate in PDAD participants was approximately double that of the observational cohort. Concordance between abnormal amyloid burden on positron emission tomography and pathologic CSF was approximately 87% (κ = 0.68; 95% CI, 0.48-0.87). No significant treatment differences were observed in the avagacestat vs placebo arm in key clinical outcome measures. CONCLUSIONS AND RELEVANCE Avagacestat did not demonstrate efficacy and was associated with adverse dose-limiting effects. This PDAD population receiving avagacestat or placebo had higher rates of clinical progression to dementia and greater brain atrophy compared with CSF biomarker-negative participants. The CSF biomarkers and amyloid positron emission tomography imaging were correlated, suggesting that either modality could be used to confirm the presence of cerebral amyloidopathy and identify PDAD. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00890890

Gamma Secretase Inhibition by BMS-906024 Enhances Efficacy of Paclitaxel in Lung Adenocarcinoma

“…GSIs were originally developed with the intent to treat Alzheimer’s disease by decreasing the formation of beta-amyloid in the brain, though clinical trials failed due to high toxicity in this population and/or poor response (9, 10). However, GSIs can be administered safely with tolerable toxicities in cancer patients as shown by phase I clinical trials in solid tumors (11, 12).…”

Alzheimer’s disease syndrome – Recognizing the complexity of dementia

“…Detailed postmortem biochemical investigations of this participant subgroup, in particular, will be extraordinarily important, but 5 years after the trial termination only a single assessment has been published [102]. Other clinical trials involving the ɣ-secretase inhibitors were also halted due to undesirable side effects [103,104]. In spite of these frustrations controlling Aβ production by modulating the activity of the β-and ɣ-secretases is being actively pursued (see Alzforum database: http:// www.alzforum.org/therapeutics).…”

Towards Personalized Intervention for Alzheimer’s Disease

“…Tau, another major hallmark of AD, is also an actively-pursued drug target [82]. Clinical trials for drugs targeting γ-secretase or tau have not been successful so far [83], [84]. While these drugs target specific molecules, Chinese traditional medicine likely has broader impact on the brain and the body as a whole.…”